Trade Mark Journal No.2021/053 31 December 2021

WO0000001631358 (5)

Office of origin: United States of America

Date of International Registration:9 November 2021
Date of designation in the UK: 9 November 2021
Image for mark 1631358 MYVOIZA

International priority date claimed: 28 October 2021 (United States of America) (97096676)
Class 5
Pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of thalassemia and sickle cell disease.

Vertex Pharmaceuticals Incorporated

Representative: Timothy H. Hiebert Womble Bond Dickinson (US) LLP, 470 Atlantic Ave., Boston MA 02210-2228, UNITED STATES OF AMERICA